ReviewJournal for immunotherapy of cancer2019
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019.
Review in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.Frontiers in oncology · 2020Pooled it
- CAR-T Cell Therapy: Pioneering Immunotherapy Paradigms in Cancer Treatment.Current pharmaceutical biotechnology · 2026Review
- Non-Malignant T Cells as Determinants of Immunotherapeutic Response in Chronic Lymphocytic Leukemia: Towards Personalized Strategies.Oncology research · 2026Review
- Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers.Medical sciences (Basel, Switzerland) · 2025Review
- CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Review
- Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Medical oncology (Northwood, London, England) · 2025Review
- Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis.American journal of blood research · 2025Review
- The importance ofMolecular biology research communications · 2025Review
- Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells.MedComm · 2024Article
- The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?Clinical hematology international · 2024Review
- Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.Frontiers in oncology · 2024Review
- Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.Journal of cellular immunology · 2024Article
- Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies.Cancer immunology, immunotherapy : CII · 2023Article
- Transcriptomic analysis of the innate immune response toMolecular therapy. Nucleic acids · 2023Article
- Current updates on generations, approvals, and clinical trials of CAR T-cell therapy.Human vaccines & immunotherapeutics · 2022Article
- Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.Stem cell research & therapy · 2022Review
- Microbial L-asparaginase as a promising enzyme for treatment of various cancers.Applied microbiology and biotechnology · 2022Review
- Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies.Asian journal of pharmaceutical sciences · 2022Article
- Development of CAR T Cell Therapy in Children-A Comprehensive Overview.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoubtedly explain the efficacy reported based on limited data for the first few series, and underlie the rationale of successive modulations in lymphodepletion schemes, transgene constructs, and, finally, the therapeutic association of CAR T cells with ibrutinib, which appears to be particularly promising. This review describes the published results and expected developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.